Pfizer generated free cash flow of $10.4 billion in the 12 months ending Sept. 30, 2025. During this period, the pharma giant ...

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...

This makes Pfizer a potentially cheap stock to buy while collecting a solid dividend. It's generated about $14 billion in ...

Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO ...

It's quite possible for the new year to fulfill this ambitious name. Investing $122,100 in these three high-yield dividend ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several ...

Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the ...

A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...

By the beginning of 2025, it was clear the GLP-1 drugs were going to remain a major part of the industry. Pfizer used its presentation at the 43 rd JP Morgan Healthcre Conference to detail plans to ...